2:57 PM
 | 
Nov 14, 2017
 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Lipodystrophy; obesity

Mouse studies suggest the FBN1 preprotein cleavage product asprosin could help treat neonatal progeroid syndrome, which is caused by FBN1 mutations, and inhibiting asprosin could help treat obesity. In a mouse model...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >